Rave RTSM: Direct-To-Patient

As the healthcare industry continues to deepen its focus on virtual trials and patient-centricity, the popularity of Direct-to-Patient (DtP) services in the clinical trial setting has grown significantly.

Rave RTSM DtP (Randomization and Trial Supply Management Direct to Patient) brings investigational medicinal products (IMP) directly to a patient’s home, bypassing the need for the patient to travel directly to a site.

Sponsors and CROs can manage DtP shipments for clinical trials or medicinal device trials. The benefits are:

• Patients are able to access customized care and novel therapies from the comfort of their homes
• Biopharmaceutical companies are able to facilitate patient enrollment and increase patient adherence, which are central to the study’s success